Highlights
- Second quarter Revenue was USD 166,131 against USD 162,910 a year earlier.
- The net loss was USD 6,283,786 against USD 7,730,117, or USD 1.46 per share.
- Cash and cash equivalents were USD 3.6 million at June 30, 2026.
- A 1-for-30 Reverse Stock Split took effect on January 1, 2026.
Co-Diagnostics, Inc. (NASDAQ:CODX) shares were trading near their all-time low at USD 0.2539 on November 6, 2026, down 4.94% on the day. The company reported second quarter revenue of USD 166,131 and a net loss of USD 6,283,786, or USD 1.46 per share.
Co-Diagnostics, a Utah corporation, develops, manufactures and sells reagents used for diagnostic tests that detect and analyze nucleic acid molecules, including DNA and RNA.
Quarter and Six-Month Results
Revenue was USD 166,131 against USD 162,910, and Gross Profit was USD 120,828 against USD 130,804. Total operating expenses were USD 6,321,611 against USD 8,188,568, and the loss from operations was USD 6,200,783 against USD 8,057,764.
For the six months ended June 30, 2026, revenue was USD 312,084 against USD 213,187. Gross profit was USD 73,013 against USD 159,491, operating expenses were USD 15,482,209 against USD 16,769,211, and the net loss was USD 15,423,824, or USD 4.69 per share, against USD 15,263,388, or USD 14.05 per share.
Cash and Liquidity
Cash and cash equivalents were USD 3,649,632 at June 30, 2026 against USD 11,884,607 at December 31, 2025. Total current Assets were USD 5.2 million against total current liabilities of USD 2.9 million.
Net cash used in Operating Activities was USD 14,999,320 for the six months against USD 17,033,044. Net cash used in investing activities was USD 310,298 against cash provided of USD 24,427,935, and net cash provided by financing activities was USD 7.1 million against USD 0.8 million.
Balance Sheet
Total assets were USD 16,590,631 against USD 24,742,585. Total liabilities were USD 3,878,282 against USD 4,113,921, and total stockholders' Equity was USD 12,712,349 against USD 20,628,664. The accumulated Deficit was USD 95,797,363.
Reverse Split and Related Party Services
All share and per-share data reflect a 1-for-30 reverse stock split effected on January 1, 2026. Weighted average shares were 4,309,997 in the quarter, and 6,252,319 shares were outstanding as of August 11, 2026.
The company has a services agreement with CoSara Diagnostics Pvt Ltd, an equity method investment, under which CoSara provides Research and Development consulting and support. The company recognized USD 262,129 and USD 488,525 of related expense under the arrangement, according to the filing.






Please wait processing your request...